RxDoctor Payments Data

Anthony Bracken, MD

Cardiovascular Disease · Charlotte, NCNPI 1770525438

Payments from drug & device makers

$365in general payments, 2019–2025

Across 11 payments — averaging $33.18 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$201
  • Novartis$50
  • ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$50
  • Abiomed$35
  • Masimo Corporation$15
  • Pfizer$14

What the payments were for

  • Food & beverage$365100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$365 in reported general payments places this provider in the 20th percentile of 727 cardiovascular disease providers in North Carolina.

See all cardiovascular disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$179,126
Medicare patients
1,296
Services billed
2,404

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban174$182,417
EntrestoSacubitril/Valsartan19$31,607
XareltoRivaroxaban21$25,561
FarxigaDapagliflozin Propanediol12$6,876
Metoprolol Succinate125$1,780
Atorvastatin Calcium137$1,180
Olmesartan Medoxomil26$877
Losartan Potassium69$665
Diltiazem 24hr Er (Cd)Diltiazem Hcl22$576
Potassium Chloride47$555
Rosuvastatin Calcium34$541
Amiodarone Hcl33$484
Amlodipine Besylate79$432
Furosemide90$417
Lisinopril46$296

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$14$182,417174 claims
NovartisEntresto$50$31,60719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 20th percentile of 727 cardiovascular disease providers in North Carolina.

Other cardiovascular disease in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →